All EV25 articles
-
NewsEradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25.
-
NewsTherapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies
Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.
-
NewsEradivir closes $10.25M Series A funding round for next stage of influenza therapeutic trials
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round which will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.